264 related articles for article (PubMed ID: 11719462)
1. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.
Yan T; Schupp JE; Hwang HS; Wagner MW; Berry SE; Strickfaden S; Veigl ML; Sedwick WD; Boothman DA; Kinsella TJ
Cancer Res; 2001 Nov; 61(22):8290-7. PubMed ID: 11719462
[TBL] [Abstract][Full Text] [Related]
2. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells.
Yan T; Berry SE; Desai AB; Kinsella TJ
Clin Cancer Res; 2003 Jun; 9(6):2327-34. PubMed ID: 12796402
[TBL] [Abstract][Full Text] [Related]
3. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation.
Davis TW; Wilson-Van Patten C; Meyers M; Kunugi KA; Cuthill S; Reznikoff C; Garces C; Boland CR; Kinsella TJ; Fishel R; Boothman DA
Cancer Res; 1998 Feb; 58(4):767-78. PubMed ID: 9485033
[TBL] [Abstract][Full Text] [Related]
4. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
5. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
[TBL] [Abstract][Full Text] [Related]
6. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
7. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells.
Berry SE; Garces C; Hwang HS; Kunugi K; Meyers M; Davis TW; Boothman DA; Kinsella TJ
Cancer Res; 1999 Apr; 59(8):1840-5. PubMed ID: 10213489
[TBL] [Abstract][Full Text] [Related]
8. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
9. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint.
Hawn MT; Umar A; Carethers JM; Marra G; Kunkel TA; Boland CR; Koi M
Cancer Res; 1995 Sep; 55(17):3721-5. PubMed ID: 7641183
[TBL] [Abstract][Full Text] [Related]
10. Estrogen up-regulates mismatch repair activity in normal and malignant endometrial glandular cells.
Miyamoto T; Shiozawa T; Kashima H; Feng YZ; Suzuki A; Kurai M; Nikaido T; Konishi I
Endocrinology; 2006 Oct; 147(10):4863-70. PubMed ID: 16825317
[TBL] [Abstract][Full Text] [Related]
11. Signalling cell cycle arrest and cell death through the MMR System.
O'Brien V; Brown R
Carcinogenesis; 2006 Apr; 27(4):682-92. PubMed ID: 16332722
[TBL] [Abstract][Full Text] [Related]
12. Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea.
Aquilina G; Ceccotti S; Martinelli S; Soddu S; Crescenzi M; Branch P; Karran P; Bignami M
Clin Cancer Res; 2000 Feb; 6(2):671-80. PubMed ID: 10690553
[TBL] [Abstract][Full Text] [Related]
13. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
Moreland NJ; Illand M; Kim YT; Paul J; Brown R
Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
Tyagi A; Singh RP; Agarwal C; Siriwardana S; Sclafani RA; Agarwal R
Carcinogenesis; 2005 Nov; 26(11):1978-87. PubMed ID: 15975956
[TBL] [Abstract][Full Text] [Related]
15. Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants.
Brieger A; Trojan J; Raedle J; Plotz G; Zeuzem S
Gut; 2002 Nov; 51(5):677-84. PubMed ID: 12377806
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.
Geisler JP; Goodheart MJ; Sood AK; Holmes RJ; Hatterman-Zogg MA; Buller RE
Cancer; 2003 Nov; 98(10):2199-206. PubMed ID: 14601090
[TBL] [Abstract][Full Text] [Related]
17. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses.
Yan T; Desai AB; Jacobberger JW; Sramkoski RM; Loh T; Kinsella TJ
Mol Cancer Ther; 2004 Sep; 3(9):1147-57. PubMed ID: 15367709
[TBL] [Abstract][Full Text] [Related]
18. The human MLH1 cDNA complements DNA mismatch repair defects in Mlh1-deficient mouse embryonic fibroblasts.
Buermeyer AB; Wilson-Van Patten C; Baker SM; Liskay RM
Cancer Res; 1999 Feb; 59(3):538-41. PubMed ID: 9973196
[TBL] [Abstract][Full Text] [Related]
19. Brostallicin (PNU-166196)--a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells.
Fedier A; Fowst C; Tursi J; Geroni C; Haller U; Marchini S; Fink D
Br J Cancer; 2003 Oct; 89(8):1559-65. PubMed ID: 14562032
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.
Hapke G; Yin MB; Wu J; Frank C; Rustum YM
Int J Oncol; 2002 Nov; 21(5):1059-66. PubMed ID: 12370755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
